Publication
Visceral disease site to predict clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA): Results of the Italian compassionate use named patient program (NPP).
Vincenza Conteduca, Orazio Caffo, Lucia Fratino, Giovanni Lo Re, Umberto Basso, Alessandro D'Angelo, Maddalena Donini, Francesco Verderame, Raffaele Ratta, Giuseppe Procopio, Enrico Campadelli, Francesco Massari, Donatello Gasparro, Paola Ermacora, Caterina Messina, Monica Giordano, Daniele Alesini, Francesca Maines, Ugo De Giorgi
Journal of Clinical Oncology, May 2015, American Society of Clinical Oncology (ASCO)
DOI: 10.1200/jco.2015.33.15_suppl.e16045